Format

Send to

Choose Destination
Wien Klin Wochenschr. 2019 May;131(Suppl 1):71-76. doi: 10.1007/s00508-018-1418-9.

["Diabesity"-Obesity and type 2 diabetes (Update 2019)].

[Article in German]

Author information

1
Klinische Abteilung für Endokrinologie und Diabetologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Auenbruggerplatz 15, 8036, Graz, Österreich. hermann.toplak@medunigraz.at.
2
Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Österreich.
3
Gender Medicine Unit, Klinische Abteilung für Endokrinologie und Stoffwechsel, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Wien, Österreich.
4
Abteilung für Innere Medizin, Krankenhaus der Barmherzigen Brüder Salzburg, Salzburg, Österreich.
5
Medizinische Abteilung, Hanusch-Krankenhaus, Wien, Österreich.
6
Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Wien, Österreich.
7
Medizinische Abteilung mit Diabetologie, Endokrinologie und Nephrologie, Krankenanstalt Rudolfstiftung, Wien, Österreich.

Abstract

For several years obesity and type 2 diabetes have been increasingly summarized under the name "diabesity". This is due to the fact that in most cases obesity precedes diabetes and is the most important risk factor for the worldwide increase of type 2 diabetes. The body mass index (BMI) is a very crude measure of body fatness in individuals. Even normal weight persons can have too much body fat in cases of a lack of muscle mass (sarcopenia), which is why additional measurements of waist circumference and body fatness, e. g. bioimpedance analysis (BIA), are recommended. Lifestyle management including nutrition modification and increase in physical activity are important measures for the prevention and treatment of diabetes. Regarding the treatment of type 2 diabetes, body weight is increasingly used as a secondary target parameter. The choice of anti-diabetic treatment and also concomitant treatment is increasingly influenced by body weight. The significance of anti-obesity medications in the treatment of type 2 diabetes will have to be clarified by future studies with body weight as the primary endpoint. Bariatric surgery is at present indicated with a BMI >35 kg/m2 with concomitant risk factors, such as diabetes and can lead at least to partial diabetes remission but has to be incorporated into an appropriate lifelong care concept.

KEYWORDS:

Body composition; Formula diets; Nutrition; Obesity; Type 2 diabetes

PMID:
30980154
DOI:
10.1007/s00508-018-1418-9

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center